Overview
- The company reported second‑quarter revenue of $753.2 million on Monday while swinging to a net loss of about $86.3 million driven by rising cost of goods and one‑time charges.
- Hims & Hers raised full‑year revenue guidance to $3.1 billion–$3.3 billion and gave Q3 revenue guidance of $880 million–$900 million while trimming the top end of its adjusted EBITDA outlook.
- Management tied the profit swing to a strategic pivot away from lower‑cost compounded GLP‑1 treatments toward higher‑priced branded drugs, plus restructuring, inventory write‑downs and costs from the Eucalyptus acquisition.
- The quarter included $47.5 million of legal contingency reserves and came after the FTC and several states filed a lawsuit alleging deceptive privacy and billing practices, which the company denies and plans to contest.
- Investors reacted to the margin hit with share declines and mixed analyst views, even as subscribers grew about 300,000 to roughly 2.9 million, leaving questions about retention, branded product pricing and near‑term margins.